The world biopharmaceutical company Abbi has recently published new data from clinical studies on parvoviruses (Gleevec previr, Pvintertaisvir), genotypic treatment, in patients with chronic hepatitis C with cirrhosis, 13 has been announced.
According to the results of experiment 3, patients who were treated with the 8th week of the parvov, 100% of patients with genotypes 1, 2, 4, 5 and 6 273 with 273) were cured.
Data from the study was presented in a recent study at the Liver Meeting® 2018 conference organized by the American Association of Liver Diseases (AASLD) in San Francisco, California.
Professor Robert S. Brown, Jr., professor of medicine at Weill Cornell Medical School and Gladys and Rollende Harriman Foundation, said: "Current guidelines do not apply to patients with hepatitis C" We are interested in a treatment option with a shorter duration of treatment that can to simplify treatment with a higher percentage of cures in patients with cirrhosis after this disease, "he said.
This analysis is based on an ongoing Phase 3b study, EXPEDITION-8, which assesses the safety and efficacy of paralytic ileus in patients with chronic C-type infection with all major genotypes (1-6). This is part of. The study included patients with hepatitis C who were cohort 1 with genotypes 1, 2, 4, 5 and 6 and cohort 2 with patients with genotype 3.
Dr. Janet Hammond, vice president of infectious disease development at Abbey, said: "Right now, mabireta has made a big difference in the lives of hepatitis C patients, but a group of patients who can benefit from shorter periods." We will continue to study and understand the value of an eight-week treatment schedule for patients, which is an important step in the fight against hepatitis C, "he said.
To date, no virological failure has been reported in cohort 1 and no patient discontinued treatment due to adverse events. Adverse events reported in the study group (over 5%) included itching (9.6%), fatigue (8.6%), headache (8.2%) and nausea (6.4%). During the study period, 6 serious (2%) adverse reactions occurred, none of which was assessed as being associated with Glecafrevir Pfisteras. No new safety tips were found in this study.
Mabillet has been approved in the US for a 12-week allogeneic treatment of patients with cirrhosis who have no experience in the treatment.